BLCM : Insider Transactions for Bellicum Pharmaceuticals, Inc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Bellicum Pharmaceuticals, Inc (BLCM)

$0.07 0.00 (0.00%) as of 4:30 Mon 3/4

Download

Exchange:

N/A

Security Type:

Common

Shares Out:

6,100,000

Market Cap:

455.98(K)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.0745 - $0.96

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	0	0	0	0
Total Sell Value	$0	$0	$0	$0
Total People Sold	0	0	0	0
Total Sell Transactions	0	0	0	0
End Date	2024-02-01	2023-10-31	2023-05-02	2022-05-02

Adjust Filter Settings

Records found: 179

Page 4 of 8

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

EVP, Technical Operations

• – –

2018-01-03

4

D

$9.79

$5,766

D/D

(589)

2,574

-

EVP, Technical Operations

• – –

2018-01-03

4

OE

$0.00

$0

D/D

1,563

3,163

-

CFO and Treasurer

• – –

2017-12-11

4

AS

$9.33

$159,667

D/D

(17,117)

31,585

-

CFO and Treasurer

• – –

2017-11-27

4

S

$9.89

$61,382

D/D

(6,206)

48,702

-

Naeve Gregory S.

Sr. VP, Chief Business Officer

• – –

2017-08-21

4

A

$0.00

$0

D/D

15,000

15,000

-

EVP, Technical Operations

• – –

2017-07-24

4

AS

$11.85

$5,178

D/D

(437)

1,600

-

Sr. VP and General Counsel

• – –

2017-07-13

4

AS

$12.26

$169,470

D/D

(13,823)

491

-

Sr. VP and General Counsel

• – –

2017-07-13

4

OE

$2.55

$35,249

D/D

13,823

14,314

-

Spencer David M.

Chief Scientific Officer

• – –

2017-07-10

4

AS

$11.54

$115,400

D/D

(10,000)

138,965

-

CFO and Treasurer

• – –

2017-05-25

4

S

$12.24

$77,254

D/D

(6,311)

54,908

-

EVP, Technical OprationsOffice

• – –

2017-05-10

3

IO

$0.00

$0

D/D

0

874

-

Baker Bros. Advisors (gp) Llc

10% Owner

– – •

2017-03-24

4

B

$12.00

$1,999,992

I/I

166,666

4,527,089

1.5

-

Slawin Kevin M.

Director

– • –

2017-02-07

4

AS

$12.54

$376,215

I/I

(30,000)

294,982

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-12-15

4

AS

$15.45

$463,539

I/I

(30,000)

324,982

-

Spencer David M.

Chief Scientific Officer

• – –

2016-12-05

4

AS

$20.00

$100,000

D/D

(5,000)

146,082

-

Spencer David M.

Chief Scientific Officer

• – –

2016-12-01

4

AS

$17.17

$87,624

D/D

(5,000)

151,082

-

Moseley Annemarie

COO/EVP Clinical Development

• – –

2016-12-01

4

AS

$17.17

$438,505

D/D

(25,000)

442

-

Moseley Annemarie

COO/EVP Clinical Development

• – –

2016-12-01

4

OE

$2.55

$63,750

D/D

25,000

25,442

-

CFO and Treasurer

• – –

2016-11-28

4

AS

$19.23

$443,160

D/D

(23,027)

60,548

-

CFO and Treasurer

• – –

2016-11-25

4

AS

$20.48

$128,480

D/D

(6,273)

83,575

-

Spencer David M.

Chief Scientific Officer

• – –

2016-09-23

4

AS

$20.19

$125,172

D/D

(6,200)

156,082

-

Sr. VP and General Counsel

• – –

2016-09-23

4

AS

$20.10

$235,198

D/D

(11,700)

344

-

Sr. VP and General Counsel

• – –

2016-09-23

4

OE

$7.47

$87,399

D/D

11,700

12,044

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-09-23

4

AS

$20.11

$240,530

I/I

(11,958)

354,982

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-09-23

4

AS

$20.12

$226,549

D/D

(11,258)

84,206

-

179 Records found	1 2 3 4 5 6 7 8	Page 4 of 8

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.